Director: Mitch A. Phelps, PhD
The Pharmacoanalytic Shared Resource (PhASR) supports pre-clinical and clinical drug development at Ohio State by providing high quality and cost-effective bioanalytical method development, quantitative sample analysis, and pharmacokinetic/pharmacodynamic experimental design, data analysis and modeling. Expertise among PhASR personnel includes quantitative pharmacology; bioanalytical methodology, design and conduct of pharmacokinetic/pharmacodynamic studies in animal disease models and in humans enrolled in clinical trials; data analysis and modeling of PK/PD data to inform drug development decisions. PhASR personnel are available for consultation on clinical or pre-clinical PK/PD experimental design and analysis.
Provide the OSUCCC – James and broader research and drug development community with:
- High-quality, state-of-the-art, cost-competitive analytical expertise and instrumentation for quantitation of drugs and metabolites in biological specimens
- Pharmacokinetic data (real-time when necessary) to enable pharmacologic data to be incorporated into clinical decision-making during dose escalation and interpretation of patient response and toxicity or in pre-clinical drug development efforts
- Expertise in pharmacokinetic/pharmacodynamic study design and data interpretation during submission of clinical protocols, grant proposals, study reports and publications
Hao Li, MS, Research Associate, is a bioanalytical chemist with more than six years’ experience in Wuxi AppTech, a global contract research service provider for the pharmaceutical industry, where he led a team of scientists as Group Leader and Assistant Director of Biaonalytical Services. Mr. Li has extensive training and experience supporting pre-clinical and clinical drug development, applying state-of-the-art LC-MS technology within an industrial GLP to study drug metabolism and disposition. Mr. Li received his BS degrees in Pharmaceutical Engineering (Jilin University) and Biotechnology (Shenyang Pharmaceutical University) and his MS in Pharmaceutical Analytics from Jilin University.
Yonghua Ling, PhD, Research Associate, is a project leader within PhASR and supports the design and conduct of studies aimed at characterizing ADME properties of novel agents in pre-clinical and early phase clinical development. She has extensive experience using LC-MS/MS for drug and metabolite quantification in biological matrices for the study of drug metabolism, absorption and distribution in animal models and in humans. Dr. Ling received her MS in analytical chemistry from Zhongshan University and her PhD in physical chemistry from the University of Miami. She completed postdoctoral training in cancer drug pharmacology at The Ohio State University under the direction of Kenneth K. Chan, PhD.
Mitch A. Phelps, PhD, Director for PhASR, is an associate professor with appointments in The Ohio State University College of Pharmacy, Division of Pharmaceutics and College of Medicine, Department of Pharmacology. Dr. Phelps has been with the OSUCCC – James for nine years applying his expertise in analytical methodologies, PK/PD study design, data analysis and modeling. A supporter of the establishment of PhASR in 2005, he drove its initial development in his previous roles as Operations Manager and Technical Director. In his current role, Dr. Phelps directs PhASR activities to develop collaborative research projects with other investigators, support PK/PD experimental design, modeling and data analysis, and to ensure resources are utilized efficiently to support high-impact science. His independent research focuses on development of novel drug therapies to treat cancer and understanding the sources of variability in outcomes of patients treated with anti-cancer and immunomodulatory agents. He is principal investigator and co-investigator on several research grants funded by the NIH and other public and private organizations. Dr. Phelps earned his PhD in Biophysics from Ohio State and completed post-doctoral training in clinical pharmacology under the mentorship of Dr. James T. Dalton. Prior to completing doctoral training, Dr. Phelps spent eight years as a chemist in private industry.
Ming Poi, PharmD, PhD, is an assistant professor in the College of Pharmacy and a Specialty Practice Pharmacist for the Investigational Drug Service (IDS) Pharmacy and Phase 1 Clinical Treatment Unit (CTU) in the James Cancer Hospital. Dr. Poi supports the design of clinical pharmacokinetic, pharmacodynamic and pharmacogenetic studies, development of clinical protocols and PK/PD/PG data analysis. In addition, she supports the design and conduct of non-clinical studies aimed at identifying genetic factors associated with variability in outcomes for patients enrolled in clinical studies at the James. Dr. Poi received her PhD in biochemistry (protein sciences) from the Ohio State University under the mentorship of Dr. Ming-Daw Tsai. She then obtained her PharmD from Ohio State’sollege of Pharmacy, followed by a pharmacy practice residency (PGY-1) at Ohio State’s Wexner Medical Center and a two-year pharmacy translational research fellowship at the OSUCCC – Jamesr.
Jiang Wang, PhD, Research Associate, is a project leader within PhASR and supports bioanalytical assay development/validation, design and conduct of pre-clinical and clinical pharmacology studies of novel anti-cancer and other agents. He has extensive expertise in quantification of small molecules and peptides in biological matrices by LC-MS/MS and other quantitative technologies that he applies to support pre-clinical and clinical pharmacology studies critical in the drug development process in collaboration with investigators at Ohio State and other institutions. After receiving his PhD in pharmacology from Jilin University, he completed postdoctoral training in molecular biology at Princeton University under the guidance of Dr. Manual Llinas, and at Ohio State in pharmaceutics under the direction of Dr. Kenneth K. Chan.
College of Pharmacy, Division of Pharmaceutics
241 Parks Hall
500 W. 12th Ave.
Columbus, OH 43210
441 OSU Biomedical Research Tower
460 W. 12th Ave.
Columbus, OH 43210
Availability: Monday – Friday
Hours: 8 a.m. – 5 p.m.